Skip to main content
. 2022 Jun 13;22:653. doi: 10.1186/s12885-022-09676-0

Table 1.

Demographics and clinical characteristics of RCC patients treated with sunitinib with a 3-month follow-up.

graphic file with name 12885_2022_9676_Tab1_HTML.jpg

ASA Acetylsalicylic acid (aspirin), ATOR Atorvastatin, GI Gastrointestinal, NA Not available, RCC Renal cell carcinoma, Patient deceased during follow-up period, ↓ Dosage Decreased dosage of sunitinib due to side effects.